/

INMB

INmune Bio Inc.Pre-market

1.68−0.10 −5.62%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

1.79

Prev close

1.78

Day range

1.641.79

52-week range

1.092.60

Volume

247.11K0.70×

Mkt cap

46.63M

P/E ttm

—

Fwd P/E

-3.91

EPS ttm

-0.6700

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−35.38%

Price Chart

Yahoo Finance · delayed

INMBOct 13, 2026O 1.77H 1.79L 1.64C 1.68−0.10 (−5.62%)Vol 247.30K

SMA 502.13
SMA 2001.64

1Y change −8.20% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

INMB INmune Bio Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −10.16%
1 month: −24.32%
3 months: −16.83%
6 months: +33.33%
Year to date: +7.69%
1 year: −8.20%

Valuation & ownership

Market cap: 46.63M
Enterprise value: 29.62M
P/E (ttm): —
Forward P/E: -3.91
PEG ratio: —
Price / book: 2.28
Price / sales (ttm): —
EV / EBITDA: —
EPS (ttm): -0.6700
EPS (forward): -0.4300
Beta (5y monthly): 0.90
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 27.75M
Float: 23.30M
Short % of float: 10.72%
Short ratio (days): 7.85
Held by insiders: 10.75%
Held by institutions: 15.59%
Avg volume (3m): 352.12K
50-day average: 2.13
200-day average: 1.64
52-week change: −8.20%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 31.0
vs 50-day SMA: −21.17%
vs 200-day SMA: +2.56%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 7.15%
Realised vol (20d, ann.): 66.8%
From 52-week high: −35.38%
From 52-week low: +54.13%

ANR

Analyst Consensus

3 analysts

Consensus

Strong buy

1.33 on a 1 (strong buy) – 5 (sell) scale

Mean target

7.00

+316.67% implied

Low 4.00Median 8.00High 9.00

Recommendation trend

Now3 / 0 / 0
1m ago4 / 0 / 0

DES

About INmune Bio Inc.

Yahoo Finance profile

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Sector: Healthcare
Industry: Biotechnology
Employees: 21
Headquarters: Boca Raton, FL, United States
Website: inmunebio.com
Officers: Mr. David J. Moss M.B.A. President, CEO, Treasurer, Secretary & Director
Mr. Cory Randall Ellspermann Interim Chief Financial Officer
Dr. Mark William Lowdell Ph.D. Co-Founder, Chair of Scientific Advisory Board, CSO & Chief Manufacturing Officer

SEAS

Seasonality · INMB

2019–2026 · monthly returns

Strongest month Jan +24.79%Weakest month Mar −13.01%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	1.9	-18.9	-12.4	26.5	-1.4	15.6	7.4	31.4	-15.2	-13.8			+7.7%
2025	117.6	-21.0	-2.7	0.6	-6.1	-68.7	18.2	-25.6	2.0	-11.6	-4.9	-10.3	−66.6%
2024	6.0	-2.8	1.3	0.8	-20.2	-6.7	-2.6	-22.9	-18.6	8.5	-13.7	-7.5	−58.5%
2023	35.3	10.0	-31.6	12.2	4.6	19.8	-5.6	-5.5	-16.4	7.7	29.6	19.2	+77.6%
2022	-1.1	-12.8	-4.3	-10.7	-8.2	28.1	1.5	-10.0	-23.2	23.7	-6.8	-11.3	−37.8%
2021	6.0	-11.1	-26.8	-0.1	14.2	29.6	-13.4	55.8	-18.1	-5.3	-30.1	-20.6	−40.8%
2020	-15.0	-9.5	-25.3	52.3	12.4	-7.9	121.3	-9.6	-1.8	-25.7	15.9	93.9	+196.9%
2019			-1.6	35.2	-3.4	-4.9	-7.2	-33.7	-1.7	-16.8	-0.8	19.1	−27.3%

INSD

Insider Activity · INMB

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jul 1, 2026	Moss David J.Chief Executive Officer	Conversion of Exercise of derivative security at price 1.40 per share.	9K	$12.62K
Jul 1, 2026	Lowdell Mark WilliamOfficer	Conversion of Exercise of derivative security at price 1.40 per share.	7.2K	$10.10K
Jul 1, 2026	Juda ScottDirector	Conversion of Exercise of derivative security at price 1.40 per share.	14.8K	$20.72K

13F

Investors Holding INMB

latest 13F filings of 29 followed managers

Investors holding INMB
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$48.4K	0.00%	29.70K	+75%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

INMB

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

INMB

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About INmune Bio Inc.

Seasonality · INMB

Insider Activity · INMB

Congress Trades · INMB

Investors Holding INMB

Investors Holding INMB

Congress Trades · INMB

Insider Activity · INMB

Seasonality · INMB

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About INmune Bio Inc.

Financial Snapshot

Earnings & Dividends

News